Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Claudia Ginsberg

Morristown, NJ Medical Doctor

NPI 1366533309 CMS profile 16346

160 Hanover Ave, Morristown, NJ 07962

Open in the dashboard

General payments

$66

4 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Claudia Ginsberg of Morristown, NJ is reported in the CMS Open Payments database as having received $66 across 4 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22 1
2023 General $32 2
2019 General $12 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Claudia Ginsberg
  • New Jersey median
  • Middle half of New Jersey
  • National median

In program year 2025, general payments to Claudia Ginsberg were reported at $22. Among 31,834 New Jersey profiles paid that year, the median was $178 and the middle half received between $51 and $585.

Show as a table
Year Claudia Ginsberg New Jersey median Middle half National median
2019 $12 $150 $44–$542 $163
2020 $0 $110 $33–$349 $114
2021 $0 $125 $36–$419 $132
2022 $0 $142 $42–$480 $149
2023 $32 $156 $48–$510 $160
2024 $0 $167 $50–$562 $164
2025 $22 $178 $51–$585 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $32 2 payments
  2. DePuy Synthes Sales Inc. $22 1 payment
  3. Ferring Pharmaceuticals Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $66 4 payments
Products named General payments · program years 2019–2025
  1. DALVANCE $32 2 payments
  2. MILAGRO $22 1 payment
  3. FMS $22 1 payment
  4. TRUESPAN ORTHOCORD $22 1 payment
  5. CHIA PERCPASSER $22 1 payment
  6. EUFLEXXA $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

579

Median for Internal Medicine: 777

Drug cost

$3,148

Median for Internal Medicine: $73,373

Branded share of claims

4.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 90 $1,324
Gabapentin Generic 60 $388
Methylprednisolone Generic 70 $363
Meloxicam Generic 157 $349
Diclofenac Sodium Generic 39 $227
Cyclobenzaprine Hcl Generic 55 $220
Prednisone Generic 52 $97
Tramadol Hcl Generic 30 $93
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 26 $87

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$282,695

Of which drugs: $74,014

Medicare patients

947

Average age 76

Services billed

8,950

701 women, 246 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Osteoporosis 30%
Ischemic heart disease 25%
Diabetes 20%
Cancer 19%
Depression 18%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 110 173 $69,905
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 418 5,534 $4,109

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

4 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record